GDC-0152

Catalog No.S7010 Batch:S701002

Print

Technical Data

Formula

C25H34N6O3S
Molecular Weight 498.64 CAS No. 873652-48-3
Solubility (25°C)* In vitro DMSO 99 mg/mL (198.54 mM)
Ethanol 99 mg/mL (198.54 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description GDC-0152 is a potent antagonist of XIAP-BIR3, ML-IAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 28 nM, 14 nM, 17 nM and 43 nM in cell-free assays, respectively; less affinity shown to cIAP1-BIR2 and cIAP2-BIR2. Phase 1.
Targets
MLXBIR3SG [1]
(Cell-free assay)		 cIAP1-BIR3 [1]
(Cell-free assay)		 XIAP-BIR3 [1]
(Cell-free assay)		 cIAP2-BIR3 [1]
(Cell-free assay)		 XIAP-BIR2 [1]
(Cell-free assay)
14 nM(Ki) 17 nM(Ki) 28 nM(Ki) 43 nM(Ki) 112 nM(Ki)
In vitro GDC-0152 can block protein−protein interactions that involve IAP proteins and pro-apoptotic molecules. Using transiently transfected HEK293T cells, GDC-0152 is shown to disrupt XIAP binding to partially processed caspase-9 and to disrupt the association of ML-IAP, cIAP1, and cIAP2 with Smac. In melanoma SK-MEL28 cells, the endogenous association of ML-IAP and Smac is effectively also abolished by GDC-0152. GDC-0152 lead to a decrease in cell viability in the MDA-MB-231 breast cancer cell line, while having no effect on normal human mammary epithelial cells (HMEC). GDC-0152 is found to activate caspases 3 and 7 in a dose- and time-dependent manner. GDC-0152 is shown to induce rapid degradation of cIAP1 in A2058 melanoma cells. It effectively induces degradation of cIAP1 at concentrations as low as 10 nM, consistent with its affinity for cIAP1.
In vivo GDC-0152 has moderate predicted hepatic clearance based on metabolic stability assays conducted using human liver microsomes. Plasma−protein binding of GDC-0152 is moderate and comparable among mice (88−91%), rats (89−91%), dogs (81−90%), monkeys (76−85%), and humans (75−83%) over the range of concentrations investigated (0.1−100 μM); higher plasma−protein binding is observed in rabbits (95−96%). GDC-0152 does not preferentially distribute to red blood cells with blood−plasma partition ratios ranging from 0.6 to 1.1 in all species tested. The pharmacokinetics for GDC-0152 is achieved with a C max of 53.7 μM and AUC of 203.5 h•μM. [1]

Protocol (from reference)

Kinase Assay:[1]
  • Fluorescence polarization-based competition assay

    Inhibition constants ( Ki ) for the antagonists are determined by addition of the IAP protein constructs to wells containing serial dilutions of the antagonists or the peptide AVPW, and the Hid-FAM probe or AVP-diPhe-FAM probe, as appropriate, in the polarization buffer. Samples are read after a 30-minute incubation. Fluorescence polarization values are plotted as a function of the antagonist concentration, and the IC50 values are obtained by fitting the data to a 4-parameter equation using software. Ki values for the antagonists are determined from the IC50 valued.
Cell Assay:[1]
  • Cell lines

    MDA-MB-231, Normal human mammary epithelial cells (HMECs)

  • Concentrations

    ~1 μM

  • Incubation Time

    72 h

  • Method

    MDA-MB-231 breast carcinoma cells and HMECs are treated with the indicated concentrations of GDC-0152. Cell death is assessed using the CellTiter-Glo luminescent cell viability assay 72 h following the start of treatment.
Animal Study:[1]
  • Animal Models

    human-tumor xenograft mouse models of MDA-MB-231 breast cancer

  • Dosages

    10, 50, or 100 mg/kg

  • Administration

    oral gavage

Customer Product Validation

, , PLoS One, 2015, 10(5):e0128647.

Data from [Data independently produced by , , Cell Death Dis, 2016, 7(8):e2325]

Data from [Data independently produced by , , Endocr Relat Cancer, 2018, 25(3):295-308]

Selleck's GDC-0152 has been cited by 22 publications

Single-molecule fingerprinting of protein-drug interaction using a funneled biological nanopore [ Nat Commun, 2023, 14(1):1461] PubMed: 37015934
Protein folding stress potentiates NLRP1 and CARD8 inflammasome activation [ Cell Rep, 2023, 42(1):111965] PubMed: 36649711
In vitro analysis reveals necroptotic signaling does not provoke DNA damage or HPRT mutations [ Cell Death Dis, 2020, 11(8):680] PubMed: 32826875
Smac Mimetics Can Provoke Lytic Cell Death That Is Neither Apoptotic Nor Necroptotic [ Apoptosis, 2020, 21] PubMed: 32440848
EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter. [ Theranostics, 2019, 9(9):2424-2438] PubMed: 31131045
HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers [ Cell Chem Biol, 2019, 26(3):331-339] PubMed: 30639259
WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway. [ Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0253-5] PubMed: 31316176
Enteroendocrine Progenitor Cell-Enriched miR-7 Regulates Intestinal Epithelial Proliferation in an Xiap-Dependent Manner. [ Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j] PubMed: 31756561
Inhibitor of Apoptosis Proteins Determines Glioblastoma Stem-Like Cell Fate in an Oxygen-Dependent Manner [ Stem Cells, 2019, 37(6):731-742] PubMed: 30920104
SMAC Mimetics Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+ T Cells. [ Cell Host Microbe, 2018, 24(5):689-702] PubMed: 30344003

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.